BMS didn’t want to choose between clinical expertise and financial know-how when selecting a new strategy leader. The Big ...

Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are ...

Life sciences investment firm Syncona has blamed the “particularly challenging” market conditions for shifting its strategy ...

The FDA has stopped new clinical trials that export American citizens’ living cells from the U.S. to “China and other hostile countries for genetic engineering and subsequent infusion” back into ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...